OTS, FUSO LAUNCH TRIAL OF OTS102

A A

OncoTherapy Science (OTS) and Fuso Pharmaceutical have announced that Japan's Pharmaceuticals and Medical Devices Agency has accepted a notification of the Phase I clinical trial plan of OTS102, an angiogenesis inhibitor currently under development by OTS.

Accordingly, the companies plan to conclude a contract with medical institutions and begin registering patients in the trial. OTS102, which consists of VEGF-R2 protein, can inhibit blood vessels from growing out of a solid tumor.